Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain - Description and associated factors - The Psychosp study

Social Psychiatry and Psychiatric Epidemiology

Volumn 39, Issue 7, 2004, Pages 507-513

  Peiró, Salvador ^a   Gómez, Gregorio ^a   Navarro, Montserrat ^b   Guadarrama, Iris ^c   Rejas, Javier ^d   Alvarez Díaz, Ana ^e   Cruz Pardo, Sonia ^e   Turrientes, Milagros Anaya ^f   Sanz Vila, Leonor ^f   Soler, Marta ^f   Díez del Pino, Alicia ^g   González Ponsjoan, Sonia ^g   Corbacho, Antonia Ma Mejías ^g   Forés Mayán, Maria ^h   Rojo, Juan ^h   Suárez, Mónica ^h   Herranz, Isabel Martín ⁱ   Yañez Rubal, Juan C ⁱ   Navarte, Amaya ^j   Vila Jato, José Luis ^j   Pla Poblador, Ramón ^k   Redondo Capafons, Susana ^k   Rivas, Josep ^l   Sorio, Francesc ^l   more..

^a Fundacion Instituto de Investigacion   (Spain)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c PFIZER INC   (United States)

^d Health Outcomes Department   (Spain)

^e HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^h HOSPITAL DE CONXO   (Spain)

ⁱ HOSPITAL JUAN CANALEJO   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k HOSPITAL MÚTUA DE TERRASSA   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Hospital costs; Length of stay; Pharmaceutical costs; Psychoses; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; ADULT; AGE DISTRIBUTION; AGED; AGGRESSIVENESS; AGITATION; CLINICAL FEATURE; DIAGNOSTIC TEST; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PSYCHIATRIC DEPARTMENT; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SPAIN;

ACUTE DISEASE; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SPAIN;

EID: 5744246783     PISSN: 09337954     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00127-004-0776-y     Document Type: Review

References (44)

1. Fuller Torrey E (1987) Prevalence studies in schizophrenia. Br J Psychiatry 150:598-698
2. Jablensky A (1995) Schizophrenia: recent epidemiologic issues. Epidemiol Rev 17:10-20
3. Jablensky A (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 250:274-285
4. Byford S, Barber JA, Fiander M, Marshall S, Green J (2001) Factors that influence the costs of caring for patients with severe psychotic illness. Br J Psychiatry 178:441-447
5. Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G (2000) Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 51:1-18
6. Guest JF, Cookson RF (1999) Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 15:597-610
7. Salvador-Carulla L, Haro JM, Cabases J, Madoz V, Sacristan JA, Vázquez-Barbero JL for the PSICOST group (1999) Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. Acta Psychiatr Scand 100:335-343
8. Haro JM, Salvador Carrulla L,Carbases J,Madoz V, Vazquez-Barquero JL (1998) Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 173:334-340
9. Rice DP, Miller LS (1998) Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 173 (Suppl):4-9
10. Amaddeo F, Beecham JK, Bonizzato P, Fenyo A, Tansella M, Knapp MRJ (1997) The use of a case register to evaluate the cost of psychiatric care. Acta Psychiatr Scand 95:195-198
11. Knapp MRJ (1997) Cost of schizophrenia. Br J Psychiatry 171: 509-518
12. Rouillon F, Toumi M, Dansette GY, Benyaya J, Auquier P (1997) Some aspects of the costs of schizophrenia.Pharmacoeconomics 11:578-594
13. Evers SMAA, Ament AJHA (1995) Cost of schizophrenia in the Netherlands. Schizophr Bull 21:141-153
14. Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21:419-429
15. Kane JM (1996) Schizophrenia. N Engl J Med 334:34-41
16. Wahlbeck K, Cheine M, Essali MA (2001) Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update software
17. Hamilton SH, Revicki DA, Genduso L, Tollefson G, Edgell E (1999) Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized trial. Pharmacoeconomics 15:469-480
18. Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B (1999) Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther 21:1105-1116
19. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I (1998) Risperidone versus haloperidol: II. Costs- effectiveness. Clin Ther 20:196-213
20. Rosenheck R, Cramer J, Xu W, et al. (1997) A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia. N Engl J Med 337:809-815
21. Procyshyn RM, Thompson D, Tse G (2000) Pharmacoeconomics of clozapine, risperidone and olanzapine. A review of the literature. CNS Drugs 13:47-76
22. Revicki DA (1999) Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 35:101-109
23. Foster RH, Goa KL (1999) Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 15: 611-640
24. Foster RH, Goa KL (1998) Risperidone: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 14:97-133
25. WHO (1999) Collaborating Centre for Drugs Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Dosis (DDDs). Oslo: World Health Organization
26. Hospital de Sagunto (1996) Memoria 1995. Sagunto: Hospital de Sagunto
27. Conselleria de Sanitat (2000) Catálogos del Sistema de Información Económica: Catálogo de pruebas de Bioquímica clínica y biología molecular. Valencia: Conselleria de Sanitat
28. Conselleria de Sanitat (2000) Catálogos del Sistema de Información Económica: Catálogo de procedimientos diagnósticos y terapéuticos de hematología. Valencia: Conselleria. de Sanitat
29. Conselleria de Sanitat (2000) Catálogos del Sistema de Información Económica: Catálogo de procedimientos de farmacia hospitalaria. Valencia: Conselleria de Sanitat
30. Conselleria de Sanitat (2000) Catálogos del Sistema de Información Económica: Catálogo de estudios de microbiología. Valencia: Conselleria de Sanitat
31. Stata Corporation (2001) Stata User's Guide Release 7. College Station, Texas: Stata Press, pp U254-U258
32. Dekker J, Peen J, Goris A, Heijnen H, Kwakman H (1997) Social deprivation and psychiatric admission rates in Amsterdam. Soc Psychiatry Psychiatr Epidemiol 32:485-492
33. Barnow S, Linden M, Schaub RT (1997) The impact of psychosocial and clinical variables on duration of in-patient treatment for depression. Soc Psychiatry Psychiatr Epidemiol 32:312-316
34. Stevens A, Hammer K, Buchkremer G (2001) A statistical model for length of psychiatric in-patient treatment and an analysis of contributing factors. Acta Psychiatr Scand 103:203-211
35. Borchardt CM, Garfinkel BD (1991) Predictors of length of stay of psychiatric adolescent in-patients. J Am Acad Child Adolesc Psychiatry 30:994-998
36. Baldessarini RJ, Kando JC, Centorrino F (1995) Hospital use of antipsychotic agents in 1989 and 1993; stable dosing with decreased length of stay. Am J Psychiatry 152:1038-1044
37. Peen J, Dekker J (2001) Social deprivation and psychiatric service use for different diagnostic groups. Soc Sci Med 53:1-8
38. Mccrone P, Phelan M (1994) Diagnosis and length of psychiatric in-patient stays. Psychol Med 24:1025-1030
39. Dickey B, Normand SLT, Norton EC, Azeni H, Fisher W, Altaffer F (1996) Managing the care of schizophrenia. Lessons from a 4-year Massachusetts Medicaid Study. Arch Gen Psychiatry 53: 945-952
40. Schubert DS,Yokley J, Sloan D, Gottesman H (1995) Impact of the interaction of depression and physical illness on a psychiatric unit's length of stay. Gen Hosp Psychiatry 17:328-334
41. Huntley DA, Cho DW, Christman J, Csernansky JG (1998) Predicting length of stay in an acute psychiatric hospital. Psychiatr Serv 49:1049-1053
42. Creed F, Tomenson B, Anthony P, Tramner M (1997) Predicting length of stay in psychiatry. Psychol Med 27:961-966
43. Priest RG, Fineberg N, Merson S, Kurian T (1995) Length of stay of acute psychiatric inpatients: an exponential model. Acta Psychiatr Scand 92:315-317
44. Oiesvold T, Saarento O, Sytema S, Christiansen L, Gostas G, Lonnerberg O, et al. (1999) The Nordic Comparative Study on Sectorized Psychiatry - length of in-patient stay. Acta Psychiatr Scand 100:220-228